-
Stay Connected
Get the latest news on exciting speakers, workshops & learning opportunities at ISDE 2021.
Subscribe for Updates
Treatment for locally advanced esophageal cancer has become more individualized. Tumor location, histology, clinical stage, operability, nutritional status, and the patient’s ability to tolerate multimodality therapy all influence whether chemoradiation is delivered before surgery or as definitive treatment.
The central goals are durable local control, prevention of distant relapse, preservation of swallowing function, and safe progression to surgery when resection is planned. Recent developments include refined radiation planning, broader use of fluoropyrimidine- and taxane-based regimens, and adjuvant immunotherapy for selected patients with residual disease.
Locally advanced disease commonly includes tumors that extend through the esophageal wall, involve regional lymph nodes, or approach adjacent structures without unequivocal metastatic spread. Accurate staging usually combines endoscopy with biopsy, contrast-enhanced CT, PET-CT, and, when appropriate, endoscopic ultrasound.
Squamous cell carcinoma and adenocarcinoma do not always follow the same treatment pathway. Squamous tumors may be particularly sensitive to radiation and can sometimes be managed with definitive chemoradiation, while resectable adenocarcinoma is frequently evaluated for perioperative chemotherapy or neoadjuvant chemoradiotherapy followed by surgery.
The CROSS regimen remains an important reference protocol for resectable disease. It combines weekly carboplatin and paclitaxel with radiation, commonly 41.4 Gy in 23 fractions, followed by esophagectomy. This approach can improve pathological response, facilitate margin-negative resection, and improve long-term outcomes compared with surgery alone.
The regimen is generally delivered over about five weeks, allowing surgery after recovery from acute treatment effects. Careful selection remains essential because severe frailty, major weight loss, poor cardiopulmonary reserve, or inadequate nutritional support can increase postoperative complications.
Definitive chemoradiation is an established option for selected patients who are medically inoperable, decline surgery, have cervical esophageal tumors, or have squamous cell carcinoma where organ preservation is a priority. Radiation doses are often around 50 to 50.4 Gy, although practice varies by tumor site, treatment intent, and institutional protocol.
Concurrent chemotherapy may use cisplatin with infusional 5-fluorouracil, or a FOLFOX-based regimen. Trials comparing FOLFOX with cisplatin/5-fluorouracil have supported FOLFOX as a practical alternative, particularly when renal function or infusion logistics make cisplatin less attractive. Definitive treatment requires close surveillance because salvage surgery may be considered for persistent or recurrent localized disease.
Modern radiation oncology increasingly uses three-dimensional conformal planning, intensity-modulated radiation therapy, and image-guided treatment. These techniques help limit dose to the heart, lungs, spinal cord, and healthy upper abdominal organs while maintaining coverage of the primary tumor and regional lymphatics.
Daily image guidance and motion assessment can improve setup accuracy, especially for tumors near the gastroesophageal junction. Proton therapy may reduce dose to selected organs in carefully chosen cases, but its availability, cost, and uncertain superiority for every patient mean that it should be considered through specialist review rather than used routinely.
The appropriate protocol depends on whether the treatment plan includes surgery, the tumor’s histology, and the patient’s overall health.
| Clinical situation | Common approach | Important considerations |
|---|---|---|
| Fit patient with resectable disease | Neoadjuvant chemoradiotherapy followed by surgery | CROSS-style therapy is widely used; nutritional and surgical assessment are essential |
| Resectable adenocarcinoma with high systemic relapse risk | Perioperative chemotherapy or chemoradiotherapy | Choice depends on stage, tumor location, histology, and multidisciplinary preference |
| Unresectable or medically inoperable squamous cell carcinoma | Definitive concurrent chemoradiation | Requires structured response assessment and surveillance |
| Patient unable to tolerate intensive chemotherapy | Modified or sequential treatment | Dose reduction, supportive care, or altered intent may be appropriate |
| Residual pathological disease after neoadjuvant therapy and surgery | Adjuvant nivolumab in eligible patients | CheckMate 577 established a role for one year of adjuvant treatment in selected patients |
A major change in management followed evidence for adjuvant nivolumab after neoadjuvant chemoradiotherapy and complete surgical resection. Patients with residual pathological disease received improved disease-free survival with nivolumab compared with placebo. This strategy is especially relevant when chemoradiation has not eradicated the tumor before surgery.
Immunotherapy is also important in advanced or metastatic disease, guided by biomarkers such as PD-L1 expression, tumor histology, and regulatory indications. It is not a universal replacement for concurrent chemotherapy, and treatment decisions should distinguish curative-intent chemoradiation from systemic therapy for disseminated cancer.
Esophagitis, odynophagia, fatigue, nausea, cytopenias, and worsening dysphagia are common during treatment. Early dietetic involvement, oral nutritional supplements, symptom-directed medication, and timely evaluation for dehydration can help patients complete therapy. Feeding access should be considered individually, particularly when severe obstruction or major malnutrition is present.
Long-term follow-up should assess anastomotic or esophageal strictures, reflux, aspiration, pulmonary effects, cardiac exposure, neuropathy, and recurrence. Endoscopic evaluation is useful when symptoms suggest persistent disease or treatment-related narrowing, while PET-CT findings must be interpreted cautiously because inflammation can resemble active cancer.
The ISDE 2021 congress community offers a valuable setting for reviewing evidence on esophageal oncology, surgical strategy, radiation technique, systemic therapy, and supportive care. Explore the congress program, scientific presentations, research abstracts, and educational resources to follow how multidisciplinary advances continue to shape care for patients with esophageal cancer.